Skip to content
Open access

Training a phage to expand its host range: directed evolution against Staphylococcus aureus from diabetic foot infections

Aug 2026 · Antimicrobial Agents and Chemotherapy · 0 citations · 46 references
Medicine

TL;DR

Both the potential and the limitations of phage training to expand therapeutic coverage are demonstrated and the need to integrate evolutionary approaches with physiologically relevant models to optimize phage therapy for chronic infections, such as DFIs is emphasized.

Abstract

ABSTRACT Diabetic foot infections (DFIs) are a major complication of diabetes frequently involving multidrug-resistant Staphylococcus aureus. Their persistence and therapeutic complexity underscore the urgent need for alternatives to conventional antibiotics. Phage therapy offers a promising solution, though its clinical application is often limited by the narrow host range of individual phages. Here, SAVM02, a recently characterized staphylococcal Kayvirus, was trained using directed evolution against DFI isolates. After 20 iterative passages on a mixed panel of susceptible and non-susceptible S. aureus strains, the trained phage pool (SAVM02-P20) displayed markedly enhanced activity, infecting approximately 77% of tested S. aureus isolates and showing partial cross-species activity against coagulase-negative staphylococci. Improved infectivity was linked to increased replication efficiency rather than adsorption. Genomic and phylogenetic analyses further suggested recurrent adaptive changes and preferential host-range expansion within genetically related lineages. In vivo testing in a zebrafish embryo model confirmed therapeutic efficacy against a fully susceptible strain but revealed no survival benefit against an initially poorly permissive isolate, highlighting the gap between in vitro adaptation and in vivo efficacy. These findings demonstrate both the potential and the limitations of phage training to expand therapeutic coverage and emphasize the need to integrate evolutionary approaches with physiologically relevant models to optimize phage therapy for chronic infections, such as DFIs.

Read PDF

Similar papers

Open access Aug 2026

Experimental evolution of phage K enhances antibacterial activity against USA300 MRSA in lung infection models

Findings highlight the value of experimental evolution for tailoring therapeutic phages and support phage adaptation as a promising strategy for developing interventions against multidrug-resistant S. aureus.

Swanti Schapp, P. Seibold, Yasmina Reisser et al. · 0 citations
Open access Sep 2026

Comprehensive characterization of Staphylococcus phage SAP_2 as a safe and effective biocontrol agent against methicillin-resistant Staphylococcus aureus

The potential of SAP_2 as a biocontrol candidate for controlling MRSA contamination in milk is supported and good biosafety and reduced bacterial burdens in MRSA-infected mice are exhibited.

Dong-Xin Ma, Shuai-Feng Gu, Yu-Qiang Zhang et al. · 0 citations
Open access Jan 2026

Characterization and Therapeutic Potential of a Novel Bacteriophage Targeting Methicillin‐Resistant Staphylococcus aureus Biofilms on Medical Devices

This is the first biologically and genomically characterized S. aureus phage from Bangladesh with demonstrated activity against MDR MRSA biofilms, highlighting its potential as a promising candidate for controlling device‐associated MRSA infections.

Raphael Kabir Niloy, Shakhinur Islam Mondal, Nurnabi Azad Jewel et al. · 0 citations
Review Aug 2026

Bacteriophage Cocktails for Combating Multidrug-Resistant Staphylococcus aureus Infections in Animals: A Comprehensive Review Across Pets, Livestock, and Wildlife.

Multidrug-resistant Staphylococcus aureus, including methicillin-resistant strains (MRSA) pose an increasing risk to animal health and are a known zoonotic risk in the One Health paradigm. The use of bacteriophage cocktails (combinations of two or more lytic phages) have gained interest for expanding host range, inhibi...

Muhammad Muneeb, A. Khan, A. Shaukat et al. · 2 citations
Open access Aug 2026

Characterization of a newly isolated broad-host-range lytic phage WEN7 against multidrug-resistant clinical Pseudomonas aeruginosa strains

Results indicate that phage WEN7 is a promising candidate for phage therapy against multidrug-resistant P. aeruginosa infections and shows strong bactericidal activity in both milk and hospital wastewater.

Chang Wen, Xiao-Hong Xiao, Jin-Yi Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.